Krystal Biotech, Inc.
Krystal Biotech is a commercial-stage biotechnology company that discovers, develops, manufactures and commercializes genetic medicines for diseases with high unmet medical needs. Its proprietary gene therapy platform uses engineered HSV-1 vectors to deliver therapeutic genes. The company operates two commercial-scale CGMP manufacturing facilities and is headquartered in Pittsburgh, Pennsylvania. Krystal’s commercial product, VYJUVEK, is a topical gene therapy for dystrophic epidermolysis bullosa, approved in the United States, the European Union and Japan. Krystal sells it directly in the United States, major European markets and Japan, and uses specialty distributors in other territories. Its clinical-stage pipeline includes candidates for cystic fibrosis, alpha-1 antitrypsin deficiency, ocular complications of dystrophic epidermolysis bullosa, neurotrophic keratitis and other diseases. The company also evaluates its platform for more common severe or life-threatening diseases and aesthetic conditions through its wholly owned subsidiary, Jeune Aesthetics.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $KRYS in the last 30 days.
See all $KRYS insider activity →Citigroup kept its Buy rating on Krystal Biotech but reduced its price target from $416 to $412, citing a 39.2% potential upside from the last close at $295.90. Other recent analyst targets for the company range from $361 to $380.
TD Cowen kept its Buy rating on Krystal Biotech but reduced its price target to $380 from $403, a 5.7% decrease. The new target suggests a 28.4% upside from the Nov 2 close of $295.90, according to the firm.
RBC Capital kept its Outperform rating on Krystal Biotech but reduced its price target from $400 to $375, a 6.2% cut. This implies a 26.7% upside from the Nov 2 close of $295.90.
Over the past 7 days, AlphAI's AI scored 18 news stories mentioning KRYS (Krystal Biotech, Inc.). Coverage has skewed bullish: 7 bullish, 7 neutral, and 4 bearish.
Recent KRYS coverage spans financial news, earnings and corporate actions.
Street valuation support remains positive (Buy), but the lower target can cap near-term upside expectations.
The PT reduction likely pressures near-term sentiment, even with the Buy rating staying intact.
Street valuation support remains positive (Outperform) but the lower target implies less upside versus prior expectations.
Earnings miss and tax hit drive negative sentiment; buyback may provide some floor support.
The buyback signals confidence and may support the stock price, while higher expense guidance could weigh on margins.
AlphAI scores every news story that mentions KRYS with an AI model for sentiment and relevance, and aggregates insider trades from Krystal Biotech, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Citigroup kept its Buy rating on Krystal Biotech but reduced its price target from $416 to $412, citing a 39.2% potential upside from the last close at $295.90. Other recent analyst targets for the company range from $361 to $380.
TD Cowen kept its Buy rating on Krystal Biotech but reduced its price target to $380 from $403, a 5.7% decrease. The new target suggests a 28.4% upside from the Nov 2 close of $295.90, according to the firm.
RBC Capital kept its Outperform rating on Krystal Biotech but reduced its price target from $400 to $375, a 6.2% cut. This implies a 26.7% upside from the Nov 2 close of $295.90.
Krystal Biotech (KRYS) reported Q3 2026 net income of $63.07M ($2.05 per share), down from $79.36M ($2.66 per share) in Q3 2025, due to higher income tax expenses. Revenues rose to $127.34M, with VYJUVEK product revenue up over 30%. The company announced market expansions for VYJUVEK and clinical trial updates. KRYS stock fell 12.78%.
Krystal Biotech (KRYS) announced a $400M share repurchase plan over 2 years and revised its 2026 non-GAAP operating expense guidance to $155M-$165M. The company aims to return value to shareholders while managing costs.
Krystal Biotech (KRYS) reported Q3 GAAP EPS of $2.05, exceeding estimates by $0.28. Revenue reached $1.1B, a 1024.7% year-over-year increase, surpassing expectations by $973.46M. The company had $1.2B in cash and investments as of September 30, 2026, with product revenue at $127.3M.
Krystal Biotech, Inc. (KRYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results $127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assess
Krystal Biotech (KRYS) will report Q3 earnings on Nov 2. Analysts expect EPS of $1.92, down 27.8% YoY, and revenue of $126.54M, up 29.4% YoY. The company has beaten estimates in 3 of the last 4 quarters, according to data. (350 characters)
The FDA issued draft guidance to accelerate personalized gene therapies for rare diseases, offering regulatory clarity for developers. The move aims to streamline approval processes for tailored treatments, benefiting companies like Ultragenyx Pharmaceutical (RARE).
Analysts raised Krystal Biotech's 12-month price target from $392.11 to $395.44, suggesting 20% upside. The consensus rating remains 'Buy' with 12 Buys, 1 Hold, and 0 Sells.
